



Model List of Essential Medicines

Amikacin

Section	Indications
Antituberculosis medicines Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Multi-drug resistant <i>Mycobacterium tuberculosis</i>
Access group antibiotics Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)	First choice Neutropenia (high-risk) co-prescribed with cefotaxime
Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime
	Acute pyelonephritis (severe) co-prescribed with ceftriaxone
	Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone
	Acute pyelonephritis (severe)
	Second choice co-prescribed with cloxacillin
	Sepsis without septic shock

Amoxicillin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid	
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection	
Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)	
Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	
Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)	
	First choice
	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
	Acute malnutrition in infants, children or adolescents (uncomplicated) [children]
	Acute malnutrition in infants, children or adolescents (complicated) [children]
	Acute pharyngitis
	Chronic obstructive pulmonary disease with acute exacerbation
	Periapical abscess without sinus
	Acute otitis media
	Acute sinusitis
	co-prescribed with gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	co-prescribed with gentamicin
	Sepsis without septic shock
	Second choice
	Bacterial meningitis
	Other indications
	Infectious cystitis
	Bacterial infection of unspecified site

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	First choice Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Second choice Osteomyelitis or osteitis Acute otitis media Other specified prophylactic measures Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) Other indications Bacterial infection of unspecified site Multi-drug resistant Mycobacterium tuberculosis
Antituberculosis medicines Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	

Ampicillin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	First choice co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritonitis (severe) co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	Second choice Bacterial meningitis
	Other indications Bacterial infection of unspecified site

Azithromycin

Section	Indications
<p>Watch group antibiotics</p> <p>Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)</p>	<p>First choice</p> <ul style="list-style-type: none">Chlamydia trachomatisTyphoid feverYawsParatyphoid feverCholeraCholera [children]Trachoma <p>co-prescribed with ceftriaxone</p> <ul style="list-style-type: none">Gonococcal infection <p>Second choice</p> <ul style="list-style-type: none">Infectious gastroenteritis or colitis without specification of infectious agent <p>co-prescribed with cefixime</p> <ul style="list-style-type: none">Gonococcal infection

Aztreonam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection</p>	<ul style="list-style-type: none">Other specified bacterial diseases

Bedaquiline

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 100 mg tablet; 20 mg tablet</p>	<ul style="list-style-type: none">Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection</p>	<p>First choice</p> <ul style="list-style-type: none">SyphilisCongenital syphilis [children] <p>Other indications</p> <ul style="list-style-type: none">Bacterial infection of unspecified site

Benzylpenicillin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)	First choice Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	
	Second choice Bacterial meningitis
	Other indications Bacterial infection of unspecified site

Capreomycin

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Parenteral > General injections > IV: 1000 mg powder for injection (vial)	

Cefalexin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	First choice Bacterial cellulitis, erysipelas or lymphangitis
Oral > Solid: 250 mg (as monohydrate)	Second choice Acute pharyngitis
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)	Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid > dispersible tablet: 125 mg; 250 mg	Other indications Bacterial infection of unspecified site

Cefazolin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	First choice Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
	Second choice Osteomyelitis or osteitis Bacterial infection of joint
	Other indications
	Surgical site infection

Cefepime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection	Other specified bacterial diseases

Cefiderocol

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection	Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant Enterobacteriales

Cefixime

Section	Indications
Watch group antibiotics Oral > Liquid: 100 mg per 5 mL powder for oral liquid Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)	Second choice Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection

Cefotaxime

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)	First choice Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) Second choice Osteomyelitis or osteitis Bacterial infection of joint Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock Other indications Bacterial infection of unspecified site

Ceftaroline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection	Other specified bacterial diseases

Ceftazidime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection</p>	<p>First choice</p> <p>co-prescribed with vancomycin</p> <p>Endophthalmitis</p> <p>Other indications</p> <p>Pseudomonas aeruginosa resistant to other antibiotic</p>

Ceftazidime + avibactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p> <p>Carbapenem resistant Enterobacteriales</p>

Ceftolozane + tazobactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 1 g + 0.5 g powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p>

Ceftriaxone

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p> <p>Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)</p>	<p>First choice</p> <p>Typhoid fever</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe) [children]</p> <p>Paratyphoid fever</p> <p>Other specified pneumonia (Hospital-acquired pneumonia)</p> <p>Bacterial meningitis</p> <p>co-prescribed with amikacin</p> <p>Acute pyelonephritis (severe)</p> <p>co-prescribed with amikacin</p> <p>Inflammatory and other diseases of prostate (severe)</p> <p>co-prescribed with azithromycin</p> <p>Gonococcal infection</p> <p>co-prescribed with clarithromycin</p> <p>Bacterial pneumonia (Community-acquired pneumonia - severe)</p>

co-prescribed with **metronidazole**

Necrotising fasciitis

co-prescribed with **metronidazole**

Peritonitis (mild-moderate)

co-prescribed with **metronidazole**

Peritonitis (severe)

co-prescribed with **metronidazole**

Peritoneal abscess (mild-moderate)

co-prescribed with **metronidazole**

Peritoneal abscess (severe)

co-prescribed with **vancomycin**

Endophthalmitis

Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Other indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt)
powder for injection; 750 mg in vial (as sodium salt) powder for injection;
1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

Chloramphenicol

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)</p> <p>Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection</p> <p>Oral > Liquid: 150 mg per 5 mL (as palmitate)</p> <p>Oral > Solid: 250 mg capsule</p>	<p>Second choice</p> <p>Bacterial meningitis</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p>

Ciprofloxacin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 2 mg per mL (as hyclate)</p> <p>Oral > Liquid: 250 mg per 5 mL (anhydrous)</p> <p>Oral > Solid: 250 mg (as hydrochloride)</p> <p>Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)</p> <p>Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)</p>	<p>First choice</p> <p>Neutropenia (low-risk)</p> <p>Inflammatory and other diseases of prostate (mild to moderate)</p> <p>Typhoid fever</p> <p>Paratyphoid fever</p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>Acute pyelonephritis (mild to moderate)</p> <p>Second choice</p> <p>Cholera</p> <p>Cholera [children]</p> <p>co-prescribed with metronidazole</p> <p>Peritoneal abscess (mild-moderate)</p> <p>co-prescribed with metronidazole</p> <p>Peritonitis (mild-moderate)</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p>

Clarithromycin

Section	Indications
Watch group antibiotics	
Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid	First choice co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe)
Parenteral > General injections > unspecified: 500 mg in vial powder for injection	co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
Oral > Solid > dosage form: 500 mg; 250 mg	
Oral > Solid > dosage form: 500 mg	Second choice Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
	Other indications Helicobacter pylori associated gastric ulcer

Clindamycin

Section	Indications
Access group antibiotics	
Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)	First choice co-prescribed with piperacillin + tazobactam Necrotising fasciitis
Oral > Solid: 150 mg (as hydrochloride) capsule	Second choice Osteomyelitis or osteitis
Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection	Bacterial infection of joint
Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)	
Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)	Other indications Bacterial infection of unspecified site
Oral > Solid: 150 mg (as hydrochloride)	

Clofazimine

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid: 100 mg; 50 mg	Leprosy
Antileprosy medicines	
Oral > Solid: 100 mg; 50 mg	

Cloxacillin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid	First choice
Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule	Bacterial infection of joint
PARENTERAL > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	Osteomyelitis or osteitis
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid	Bacterial cellulitis, erysipelas or lymphangitis
PARENTERAL > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection	Second choice
Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)	co-prescribed with amikacin
	Sepsis without septic shock
	Other indications
	Bacterial infection of unspecified site

Colistin (injection)

Section	Indications
Reserve group antibiotics	
PARENTERAL > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)	Other specified bacterial diseases
PARENTERAL > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)	Carbapenem resistant Acinetobacter baumannii
	Carbapenem-resistant Pseudomonas aeruginosa
	Carbapenem resistant Enterobacterales

Cycloserine

Section	Indications
Antituberculosis medicines	
Oral > Solid: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

Dapsone

Section	Indications
Antileprosy medicines	
Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	Leprosy

Daptomycin

Section	Indications
Reserve group antibiotics	
PARENTERAL > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Delafloxacin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 300 mg lyophilized powder for injection</p> <p>Oral > Solid: 450 mg</p>	Methicillin resistant <i>Staphylococcus aureus</i>

Delamanid

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid > dispersible tablet: 25 mg</p> <p>Oral > Solid > tablet: 50 mg</p>	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Doxycycline

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)</p> <p>Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)</p> <p>Parenteral > General injections > unspecified: 100 mg in vial powder for injection</p> <p>Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)</p> <p>Oral > Solid > dispersible tablet: 100 mg (as monohydrate)</p> <p>Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)</p> <p>Oral > Solid > dosage form: 100 mg (as hyclate)</p>	<p>First choice</p> <p><i>Chlamydia trachomatis</i></p> <p><i>Cholera</i></p> <p>Second choice</p> <p><i>Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)</i></p> <p><i>Chronic obstructive pulmonary disease with acute exacerbation</i></p> <p><i>Cholera [children]</i></p> <p>Other indications</p> <p><i>Bacterial infection of unspecified site</i></p>

Eravacycline

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 50 mg lyophilized powder for injection</p>	Carbapenem resistant <i>Enterobacteriales</i>

Erythromycin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)</p> <p>Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)</p> <p>Oral > Solid: 250 mg (as stearate or ethylsuccinate)</p>	<p>Second choice</p> <p>Therapeutic equivalent to clarithromycin for</p> <p>Acute pharyngitis</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p>

Ethambutol

Section	Indications
<p>Antituberculosis medicines</p> <p>Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL</p> <p>Oral > Solid > dispersible tablet: 100 mg</p> <p>Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)</p>	<p>Other specified tuberculosis</p> <p>Tuberculosis</p>

Ethambutol + isoniazid

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 400 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethambutol + isoniazid + rifampicin

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid: 275 mg + 75 mg + 150 mg tablet</p>	<p>Tuberculosis</p>

Ethionamide

Section	Indications
<p>Antituberculosis medicines</p> <p>Oral > Solid > dispersible tablet: 125 mg</p> <p>Oral > Solid > tablet: 250 mg</p>	<p>Multi-drug resistant Mycobacterium tuberculosis</p> <p>Tuberculous meningitis</p>

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Flomoxef

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection	Other specified other antibiotic resistant Enterobacteriales

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

Gatifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Gentamicin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neonatal meningitis

co-prescribed with amoxicillin

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Sepsis without septic shock

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Peritonitis (severe)

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with benzylpenicillin

Sepsis without septic shock

Second choice

Other specified prophylactic measures

Gonococcal infection

Other indications

Bacterial infection of unspecified site

Imipenem + cilastatin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	Second choice Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe)
Antituberculosis medicines	Other indications Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection	Other specified other antibiotic resistant Enterobacterales Carbapenem resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa

Isoniazid

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 100 mg per mL Oral > Solid > dispersible tablet: 100 mg Oral > Solid > tablet: 100 mg; 300 mg	Other specified tuberculosis Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg	Tuberculosis

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid > dispersible tablet: 50 mg + 75 mg	
Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg	

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines	Latent tuberculosis
Oral > Solid: 300 mg + 300 mg tablet (scored)	

Kanamycin (injection)

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Parenteral > General injections > IV: 1000 mg powder for injection (vial)	

Levofloxacin

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid > dispersible tablet: 100 mg	
Oral > Solid > tablet: 250 mg; 500 mg; 750 mg	

Linezolid

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases
Parenteral > General injections > IV: 2 mg per mL in 300 mL bag	Methicillin resistant Staphylococcus aureus
Oral > Liquid: 100 mg per 5 mL powder for oral liquid	Vancomycin resistant Staphylococcus aureus
Oral > Solid: 400 mg tablet; 600 mg tablet	Vancomycin resistant Enterococcus
Oral > Solid > dispersible tablet: 150 mg	
Oral > Solid > tablet: 600 mg	
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid > dispersible tablet: 150 mg	
Oral > Solid > tablet: 600 mg	

Meropenem

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Second choice Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
Antituberculosis medicines Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant Mycobacterium tuberculosis

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i> Carbapenem resistant <i>Acinetobacter baumannii</i>

Metronidazole

Section	Indications
Access group antibiotics	
Oral > Liquid: 200 mg per 5 mL (as benzoate)	First choice
Oral > Solid: 200 to 500 mg tablet	Intestinal infections due to <i>Clostridioides difficile</i>
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection	Trichomoniasis
Local > Rectal > Suppository: 500 mg; 1 g	co-prescribed with cefazolin
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial	Other specified prophylactic measures
Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg	co-prescribed with cefotaxime
	Peritonitis (severe)
	co-prescribed with cefotaxime
	Peritonitis (mild-moderate)
	co-prescribed with cefotaxime
	Peritoneal abscess (mild-moderate)
	co-prescribed with cefotaxime
	Peritoneal abscess (severe)
	co-prescribed with ceftriaxone
	Necrotising fasciitis
	co-prescribed with ceftriaxone
	Peritonitis (severe)
	co-prescribed with ceftriaxone
	Peritoneal abscess (mild-moderate)
	co-prescribed with ceftriaxone
	Peritoneal abscess (severe)
	co-prescribed with ceftriaxone
	Peritonitis (mild-moderate)
	Second choice
	co-prescribed with ciprofloxacin
	Peritonitis (mild-moderate)
	co-prescribed with ciprofloxacin
	Peritoneal abscess (mild-moderate)
	Other indications
	Bacterial infection of unspecified site

Moxifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 100 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>
Oral > Solid > tablet: 400 mg	Tuberculosis

Nitrofurantoin

Section	Indications
Access group antibiotics Oral > Liquid: 25 mg per 5 mL oral liquid Oral > Solid > dosage form: 100 mg; 50 mg	First choice Infectious cystitis

Ofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Omadacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 100 mg lyophilized powder for injection Oral > Solid: 300 mg	Methicillin resistant <i>Staphylococcus aureus</i>

Oxazolidinones

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

Phenoxymethylpenicillin

Section	Indications
Access group antibiotics	First choice
Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid	Acute pharyngitis
Oral > Solid: 250 mg (as potassium salt) tablet	Periapical abscess without sinus
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
	Other indications
	Bacterial infection of unspecified site

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics	First choice
Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (high-risk) Peritonitis (severe) co-prescribed with clindamycin Necrotising fasciitis

Plazomicin

Section	Indications
Reserve group antibiotics	Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacteriales

Polymyxin B (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)	Carbapenem resistant <i>Acinetobacter baumannii</i> Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i>

Polymyxins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Pretomanid

Section	Indications
Antituberculosis medicines Oral > Solid > tablet: 200 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Procaine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	First choice <i>Congenital syphilis [children]</i> Second choice <i>Syphilis</i>

Protonamide

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to <i>ethionamide</i> for Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Pyrazinamide

Section	Indications
Antituberculosis medicines Oral > Solid > dispersible tablet: 150 mg Oral > Solid > tablet: 400 mg; 500 mg	Tuberculosis

Rifabutin

Section	Indications
Antituberculosis medicines Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Liquid: 20 mg per mL	Other specified tuberculosis
Oral > Solid: 150 mg; 300 mg	
Parenteral > General injections > IV: 600 mg in vial powder for injection	
Antileprosy medicines	Leprosy
Oral > Liquid: 20 mg per mL	
Oral > Solid: 150 mg; 300 mg	

Rifapentine

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid > tablet: 150 mg; 300 mg	Latent tuberculosis

Spectinomycin

Section	Indications
Access group antibiotics	Second choice
Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Gonococcal infection
	Other indications
	Bacterial infection of unspecified site

Streptomycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Sulfamethoxazole + trimethoprim

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule</p> <p>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid</p> <p>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet</p> <p>Oral > Solid > dispersible tablet: 100 mg + 20 mg</p>	<p>First choice</p> <p>Infectious cystitis</p> <p>Second choice</p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p>

Tedizolid

Section	Indications
<p>Reserve group antibiotics</p>	<p>Therapeutic equivalent to linezolid for</p> <p>Methicillin resistant <i>Staphylococcus aureus</i></p> <p>Therapeutic equivalent to linezolid for</p> <p>Vancomycin resistant <i>Staphylococcus aureus</i></p> <p>Therapeutic equivalent to linezolid for</p> <p>Vancomycin resistant <i>Enterococcus</i></p>

Terizidone

Section	Indications
<p>Antituberculosis medicines</p>	<p>Therapeutic equivalent to cycloserine for</p> <p>Multi-drug resistant <i>Mycobacterium tuberculosis</i></p>

Tetracycline

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Solid: 250 mg (hydrochloride)</p>	<p>Bacterial infection of unspecified site</p>

Tigecycline

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 50 mg in vial powder for injection</p>	<p>Other specified bacterial diseases</p>

Trimethoprim

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 50 mg per mL</p> <p>Oral > Solid: 100 mg; 200 mg</p>	<p>First choice</p> <p>Infectious cystitis</p>

Vancomycin

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection</p> <p>Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)</p> <p>Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection</p> <p>Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection</p>	<p>First choice</p> <p>Necrotising fasciitis</p> <p>co-prescribed with ceftazidime</p> <p>Endophthalmitis</p> <p>co-prescribed with ceftriaxone</p> <p>Endophthalmitis</p> <p>Second choice</p> <p>Neutropenia (high-risk)</p> <p>Intestinal infections due to Clostridioides difficile</p> <p>Other indications</p> <p>Methicillin resistant Staphylococcus aureus</p>